Clinical Trials
915
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (840 trials with phase data)• Click on a phase to view related trials
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 882
- Registration Number
- NCT07196748
- Locations
- 🇺🇸
Gastro Intestinal Research Institute of Northern Ohio LLC, Westlake, Ohio, United States
🇺🇸University Gastroenterology, Providence, Rhode Island, United States
🇺🇸Tyler Research Institute, LLC, Tyler, Texas, United States
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1092
- Registration Number
- NCT07196722
- Locations
- 🇺🇸
Gastro Intestinal Research Institute of Northern Ohio LLC, Westlake, Ohio, United States
🇺🇸University Gastroenterology, Providence, Rhode Island, United States
🇺🇸Tyler Research Institute, LLC, Tyler, Texas, United States
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
- Conditions
- Hemolytic Disease of the Fetus and Newborn
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 175
- Registration Number
- NCT07194070
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇮🇹Fondazione Policlinico Universitario A Gemelli IRCCS, Roma, Italy
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Interventions
- Biological: PasritamigOther: PlaceboDrug: Best Supportive Care (BSC)
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 663
- Registration Number
- NCT07164443
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇦🇺Warringal Private Hospital, Heidelberg, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT07149857
- Locations
- 🇪🇸
Hosp. Clinic de Barcelona, Barcelona, Spain
🇪🇸Hosp. Univ. 12 de Octubre, Madrid, Spain
🇪🇸Clinica Univ. de Navarra, Pamplona, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 179
- Next
News
Targeted Drug Combination Induces Remission in CLL Patients, Improving Survival and Quality of Life
A phase III clinical trial, FLAIR, demonstrated that a combination of venetoclax and ibrutinib is more effective than chemotherapy for chronic lymphocytic leukemia (CLL).